System-independent quantitative cardiac CT perfusion

系统独立的定量心脏 CT 灌注

• 批准号: 10458469
• 负责人: DEBASHISH ROY
• 金额: $ 100.55万
• 依托单位: BIOINVISION, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10458469
• 关键词: 3-Dimensional; Accident and Emergency department; Affect; Algorithms; Anatomy; Angiography; Attention; Biomedical Engineering; Blood flow; Calibration; Cardiac; Cardiac Volume; Cardiovascular Diseases; Cardiovascular system; Cause of Death; Chest Pain; Clinical; Clinical Data; Computer software; Confidence Intervals; Coronary; Coronary Angiography; Coronary artery; Cost Savings; Data; Decision Making; Detection; Development; Diabetes Mellitus; Diagnostic; Diffuse; Disease; Dose; Electrocardiogram; Environment; Evaluation; Family suidae; Heart; Image; Imaging Phantoms; Imaging Techniques; Intervention; Iodine; Ischemia; Lead; Licensing; Machine Learning; Magnetic Resonance Imaging; Manufacturer Name; Maps; Measurement; Medical center; Methods; Microvascular Dysfunction; Modality; Myocardial; Obesity; Partner in relationship; Pathway interactions; Patient risk; Patients; Performance; Perfusion; Persons; Phase; Physiological; Positron-Emission Tomography; Prevalence; Process; Publications; Publishing; Research; Resolution; Roentgen Rays; Role; Sales; Scanning; Small Business Innovation Research Grant; Standardization; Stenosis; Stents; System; Testing; Therapeutic Intervention; Time; Tissues; Universities; University Hospitals; Vendor; Woman; X-Ray Computed Tomography; blood flow measurement; cardiovascular imaging; commercialization; coronary perfusion; cost; digital; improved; indexing; innovation; interest; performance tests; pre-clinical; prospective; prototype; research clinical testing; single photon emission computed tomography; software development; success; three-dimensional visualization; tool; trustworthiness; usability; virtual

System-independent quantitative cardiac CT perfusion Phase II, SBIR Summary BioInVision, Inc. and team - Case Western Reserve University (CWRU) biomedical engineers and University Hospitals Cleveland Medical Center (UH) imaging cardiologists - will develop software for quantitative analysis of cardiac CT perfusion (CCTP) data, creating an important tool for evaluation of cardiovascular disease. With this product, cardiologists will be able to identify functional flow deficits in coronary artery territories. When one combines functional myocardial blood flow (MBF) function with coronary anatomy from coronary computed to- mography angiography (CCTA), it provides needed information on the physiologic significance of a stenosis. The CCTP+CCTA combination could provide an ideal gateway exam for deciding whether to send a patient for percutaneous invasive coronary angiography and potential intervention (e.g., stenting). In addition, low flow with- out the presence of a stenosis suggests microvascular disease, a very prevalent ailment of growing concern, especially among women and diabetes patients. CT compares favorably to all other non-invasive cardiovascular imaging techniques (SPECT, PET, and MRI). It is available in many settings, including emergency departments, and is high throughput as compared to other methods. It provides both MBF and reliable coronary anatomy, with are unavailable in any other single modality, providing a unique ability to non-invasively discriminate cardiac microvascular disease. It has excellent resolution enabling detection of endocardial perfusion deficit, thought to be an early disease indicator that is impossible to assess with SPECT. CT is cheaper and has higher patient throughput than MRI or PET. With the inclusion of MBF, CT would have an excellent opportunity to disrupt the diagnostic pathway leading to percutaneous intervention, a pathway which has been dominated by SPECT my- ocardial imaging, a modality that gives zero information about coronary anatomy. To achieve reliable, accurate CT MBF measurements, we will invoke innovations to reduce beam hardening and to make reliable flow esti- mates. Currently, CT perfusion is done on different CT machines with manufacturers’ proprietary software, using algorithms that can give erroneous MBFs. Applicable to any commercial scanner; our solution would harmonize measurements across acquisition systems providing trustworthy, standardized measurements to clinicians, thereby improving management of cardiovascular patients.

无独立的定量心脏CT灌注 第二阶段，Sbir 概括 BioInvision，Inc。和Team -Case Western Reserve University（CWRU）生物医学工程师和大学 医院克利夫兰医疗中心（UH）成像心脏病专家 - 将开发用于定量分析的软件 心脏CT灌注（CCTP）数据，创造了评估心血管疾病的重要工具。和 该产品，心脏病专家将能够识别功能流在冠状动脉领土中定义。当一个 将功能性心肌血流（MBF）功能与冠状动脉解剖结合了计算的冠状动脉解剖结构 moghation血管造影（CCTA），它提供了有关狭窄的生理意义的所需信息。 CCTP+CCTA组合可以提供理想的门户考试，以决定是否送患者 经皮浸润性冠状动脉造影和潜在干预（例如支架）。另外，低流量与 出现狭窄的存在表明微血管疾病是一种非常普遍的关注的疾病， 特别是在女性和糖尿病患者中。 CT与所有其他非侵入性心血管相比 成像技术（SPECT，PET和MRI）。它在包括急诊室在内的许多情况下可用， 与其他方法相比，吞吐量很高。它提供MBF和可靠的冠状动脉解剖结构 在任何其他单一模式中都无法获得，提供了独特的非侵入性心脏的能力 微血管疾病。它具有出色的分辨率，可以检测到心内膜灌注防御的检测 成为早期疾病指标，无法通过SPEC进行评估。 CT便宜，患者更高 吞吐量比MRI或PET。随着MBF的包括，CT将有一个绝佳的机会破坏 导致经皮干预的诊断途径，这是一种由Spect my-主导的途径 心脏成像，一种形式，赋予有关冠状动脉解剖结构的零信息。实现可靠，准确的 CT MBF测量值，我们将援引创新以减少光束硬化并进行可靠的流量估算 伴侣。目前，使用制造商的专有软件在不同的CT机器上进行CT灌注，并使用 可能会产生错误的MBF的算法。适用于任何商业扫描仪；我们的解决方案将协调 跨采集系统的测量，为临床医生提供值得信赖的标准化测量， 从而改善了心血管患者的管理。